Project Grant P01CA281826
Award Date
9/11/24
Completion Date
8/31/29
Dollars Obligated
$3.5M
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94143, USA
Similar Awards
This federal Project Grant award of $505,613 from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) will fund the development of statistical and computational approaches to leverage genomic data for precision cancer prevention. The key products and services to be delivered include: Deep learning-based methods to identify tumor heterogeneity and predictive biomarkers of aggressive cancer, integrating spatial omics data. Statistical...
This federal Project Grant award, provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), supports a $644,804 research project titled "Advancing Breast Cancer Risk Assessment for Black Women." The project aims to develop and validate a novel deep learning-based breast cancer risk assessment tool focused on Black women, leveraging digital breast tomosynthesis (DBT) imaging data. Key objectives include: Developing a DBT-driven...
The National Cancer Institute (NCI) awarded a $680,433 Project Grant under CFDA 93.394 - Cancer Detection and Diagnosis Research to The Regents of the University of California, San Francisco (UCSF) to conduct a multi-year research project titled "Multimodality Spatial Analysis in Prostate Cancer to Improve Prognostic Estimation and Cast Light into the Black Box of Pathology Artificial Intelligence Algorithms." The goal of this research is to apply cutting-edge spatial proteogenomic...
The National Cancer Institute (NCI) awarded a $734,785 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to Vanderbilt University Medical Center. The 5-year grant, effective September 1, 2024, will fund a proteogenomics study to identify proteins associated with breast cancer risk. The study will integrate genomics and proteomics data from over 5,000 normal breast tissue samples and 125 breast cancer tissue samples to discover putative target proteins for...
This $989,122 Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to evaluate the performance of four commercial mammography-based artificial intelligence (AI) algorithms for breast cancer risk prediction in diverse U.S. screening populations. The project will assess the accuracy and equity of these AI risk models compared to traditional clinical risk factor-based models, using data from the Breast Cancer...
This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $572,490 to The Regents of the University of California, San Francisco (UCSF) to develop an AI-powered tool called PILLAR. PILLAR aims to accurately predict breast cancer risk using longitudinal multi-modal breast imaging data, including mammograms, tomosynthesis, and MRIs. The key objectives are to: 1) develop the PILLAR AI model to improve upon current clinical...
The National Cancer Institute (NCI) awarded a 5-year, $1,504,098 Project Grant (CFDA 93.393 - Cancer Cause and Prevention Research) to the Sloan-Kettering Institute for Cancer Research in New York. The grant, which commenced on May 6, 2025, seeks to identify genetic determinants of radiation-associated contralateral breast cancer (CBC) and develop a comprehensive model to estimate CBC risk. The research leverages the extensive WECARE study cohort of 1,233 CBC cases and 1,746 matched unilateral...
This Project Grant award from the National Cancer Institute (CFDA 93.394, Cancer Detection and Diagnosis Research) to The Regents of the University of California, San Francisco (UCSF) provides $391,703 from May 1, 2025 to April 30, 2028 to develop rapid, sensitive, and reproducible platforms for screening drugs in a preclinical setting using patient-derived breast cancer organoids. The project aims to improve the uniformity, reproducibility, and physiological relevance of organoid models to...
The National Cancer Institute (NCI) awarded a $872,878 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the University of California, Davis (UC Davis) to conduct the Latin America Genomics of Breast Cancer Risk Study (LAGENO-BCR). The five-year project, which began on September 1, 2024, aims to study the genetic architecture of breast cancer risk in Hispanic/Latina populations and improve predictive models for risk stratification. The project leverages the...
The National Cancer Institute (NCI) awarded a Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to The Regents of the University of California, San Francisco (UCSF) totaling $679,188. The grant will fund the development of liquid biopsy tests using artificial intelligence-assisted, morphology-based isolation of tumor cells from malignant effusions to evaluate known actionable breast cancer biomarkers and discover new predictive molecular and morphology-based...